Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Lack

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
British Journal of Pharmacology|April 6, 2017
Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approachAli Ryan, Elena Polycarpou, Nathan A Lack, et al.
Journal of the American Chemical Society|October 22, 2025
Baited SELEX: Drug-Directed Selection of Aptamers to PSMA for <i>In Vivo</i> Targeting of Prostate Cancer Xenografts in MiceKun Liu, Nicole Robinson, Emirhan Tekoglu, et al.
Molecular Cancer Therapeutics|August 14, 2013
Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancerHuifang Li, Mohamed D H Hassona, Nathan A Lack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2026
Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic TargetShivang Sharma, Nikita Mundhara, Emirhan Tekoglu, et al.
Cancers|July 24, 2021
Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate CancerFuqiang Ban, Eric Leblanc, Ayse Derya Cavga, et al.
Experimental & Molecular Medicine|June 29, 2025
Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancerOzlem Yedier-Bayram, Ahmet Cingöz, Ebru Yilmaz, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2025
AR-V7 condensates drive androgen-independent transcription in castration resistant prostate cancerShabnam Massah, Nicholas Pinette, Jane Foo, et al.
The Journal of Antimicrobial Chemotherapy|February 8, 2018
Impact of the ST101 clone on fatality among patients with colistin-resistant Klebsiella pneumoniae infectionFusun Can, Sirin Menekse, Pelin Ispir, et al.
Genome Research|May 8, 2024
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regionsStacey E P Joosten, Sebastian Gregoricchio, Suzan Stelloo, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancerLarysa Poluben, Mannan Nouri, Jiaqian Liang, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
British Journal of Pharmacology|April 6, 2017
Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approachAli Ryan, Elena Polycarpou, Nathan A Lack, et al.
Journal of the American Chemical Society|October 22, 2025
Baited SELEX: Drug-Directed Selection of Aptamers to PSMA for <i>In Vivo</i> Targeting of Prostate Cancer Xenografts in MiceKun Liu, Nicole Robinson, Emirhan Tekoglu, et al.
Molecular Cancer Therapeutics|August 14, 2013
Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancerHuifang Li, Mohamed D H Hassona, Nathan A Lack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2026
Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly-Expressed, Combinatorial Therapeutic TargetShivang Sharma, Nikita Mundhara, Emirhan Tekoglu, et al.
Cancers|July 24, 2021
Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate CancerFuqiang Ban, Eric Leblanc, Ayse Derya Cavga, et al.
Experimental & Molecular Medicine|June 29, 2025
Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancerOzlem Yedier-Bayram, Ahmet Cingöz, Ebru Yilmaz, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2025
AR-V7 condensates drive androgen-independent transcription in castration resistant prostate cancerShabnam Massah, Nicholas Pinette, Jane Foo, et al.
The Journal of Antimicrobial Chemotherapy|February 8, 2018
Impact of the ST101 clone on fatality among patients with colistin-resistant Klebsiella pneumoniae infectionFusun Can, Sirin Menekse, Pelin Ispir, et al.
Genome Research|May 8, 2024
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regionsStacey E P Joosten, Sebastian Gregoricchio, Suzan Stelloo, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2024
Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancerLarysa Poluben, Mannan Nouri, Jiaqian Liang, et al.
Pageof 12